About
Kamada Ltd develops plasma-derived protein therapeutics for orphan diseases, utilizing proprietary extraction and purification technology to produce highly-purified protein treatments including Glassia, approved by the US FDA for emphysema due to genetic deficiency.
Explore Kamada Ltd's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.